September 29, 2015
In this issue, we cover healthcare market trends and challenges, M&A trends, and regulatory developments in the Asia-Pacific region.
September 23, 2015
The 2015 PwC pharmaceutical industry survey captures the collective views of the Australian pharma sector and explores the industry's key challenges, trends and opportunities.
May 04, 2015
PwC's Global Health Industries network is pleased to present you with its 13th issue of the Asia-Pacific Health Industries Newsletter.
April 16, 2015
PwC’s 2015 State of the Internal Audit Profession Study reflects the views of more than 1300 chief audit executives, senior management and board members.
December 23, 2014
PwC's Global Health Industries network is pleased to present you with its 12th issue of the Asia-Pacific Health Industries Newsletter.
July 25, 2014
In this edition we highlight recent developments in Asia and Australia including changes in China's compliance and pricing environment, pharmaceutical deals in South Korea and India, digital health, Big Data, and tax developments in Australia, Hong Kong, China and Singapore.
June 26, 2014
PwC researches pharma relationship performance in large scale clinical outsourcing and lessons from R&D outsourcing in other hi-tech industries.
May 16, 2014
This PwC publications surveys pharmaceutical executives across the pharmaceutical value chain about the challenges on innovation in the sector.
October 23, 2013
This article lays out these and other key issues you may be facing, and offers guidance on how to bring your transfer pricing strategies up to date - while managing the expectations of multiple stakeholders.
March 22, 2013
This PwC publication provies news and analysis for pharmaceutical, biotechnology, medical device, diagnostic and healthcare companies.
November 15, 2012
In this report, we focus on how companies can reach 2020 in a position to benefit from more favourable conditions thereafter.
August 01, 2012
Asia-Pacific Pharma Newsletter, Issue 9, covers compliance updates in Australia, government price cuts in the region and tax issues in Australia, China, India, Taiwan and Singapore.
April 30, 2012
This PwC newsletter includes reports on the recent Indian and Singapore Budgets and the implications for multinationals and the local Pharma and Healthcare sectors.
April 30, 2012
PwC recently surveyed executives from leading global and domestic Medtech companies with India operations representing $1.3 billion in revenues in India, or roughly 40% of the $3 billion Indian market. Their responses, combined with in-depth interviews and PwC’s research and experience in the industry, provide insight on how to succeed in India.
January 16, 2012
PwC's Pharma 2020 series reports look into the future of the Pharmaceuticals and Life Sciences’ value chain, and they include an analysis of the strategies needed to compete successfully in the future.
December 05, 2011
PwC’s Diagnostics 2011 provides an overview of M&A deal activity during the past two years and the factors driving it, including the advance of personalised medicine and testing for earlier detection of diseases, such as cancer and Alzheimer’s. The report also includes an in-depth discussion about trends in companion diagnostics and business model considerations for pharmaceutical companies.
February 20, 2011
PwC's report discusses how pharma companies must develop different supply chain models for different product types and patient segments, use their supply chains for market differentiation and see the role information plays to drive the flow of products and services.
January 25, 2011
Puerto Rico issued final regulations December 29, 2010, under Act 154, which modifies Puerto Rican (PR) tax law by adopting new source-of-income rules and imposing a temporary excise tax on certain purchases by offshore companies whose gross receipts exceed $75 million. The new regulations follow the signing of Act 154 by Governor Luis G. Fortuño October 25, 2010, during a rare weekend legislative session. The law, enacted as part of a tax reform initiative, could raise an estimated $5.8 billion over the next six years.
December 08, 2010
Poland remains the largest clinical trials market in CEE/CIS, however, both patient participation and site penetration rates indicate a potential for growth. Launching a number of initiatives will accelerate the market growth and maximize the potential benefits to the economy.
November 02, 2010